StockDuty ← Dashboard Nov 17, 2026 03:09 AM ET
SignalCorporate

Prestige Consumer Healthcare (PBH) Stock May Be Undervalued Despite Lowered Revenue Guidance

Prestige Consumer Healthcare stock may be undervalued despite lowered revenue guidance.

What happened: Prestige Consumer Healthcare ($PBH) shares are down sharply this year, and coverage questions whether the current price is supported by earnings after management trimmed revenue and EPS guidance. Key numbers: Share price US$48.00, down 21.6% year to date. P/E 14.7x versus Pharmaceuticals industry average 17.1x and peer group average 19.9x. Why it matters: The guidance cut stems from supply constraints in the Clear Eyes product line, which the content says can affect views on the reliability of cash generation. The P/E discount persists even after expectations were reset. Market: +3.9% today ($48.00), -21.6% YTD, 0.8x vol — as of 23:47 UTC
Prestige Consumer Healthcare ($PBH) shares are down sharply this year, and coverage questions whether the current price is supported by earnings after management trimmed revenue and EPS guidance.
The guidance cut stems from supply constraints in the Clear Eyes product line, which the content says can affect views on the reliability of cash generation. The P/E discount persists even after expectations were reset. Market: +3.9% today ($48.00), -21.6% YTD, 0.8x vol — as of 23:47 UTC
Sources